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Improved single-swab sample preparation
for recovering bacterial and phage DNA
from human skin and wound microbiomes
Samuel Verbanic1,2, Colin Y. Kim1, John M. Deacon3 and Irene A. Chen1,2,4*
Abstract
Background: Characterization of the skin and wound microbiome is of high biomedical interest, but is hampered
by the low biomass of typical samples. While sample preparation from other microbiomes (e.g., gut) has been the
subject of extensive optimization, procedures for skin and wound microbiomes have received relatively little
attention. Here we describe an improved method for obtaining both phage and microbial DNA from a single skin
or wound swab, characterize the yield of DNA in model samples, and demonstrate the utility of this approach with
samples collected from a wound clinic.
Results: We find a substantial improvement when processing wound samples in particular; while only one-quarter
of wound samples processed by a traditional method yielded sufficient DNA for downstream analysis, all samples
processed using the improved method yielded sufficient DNA. Moreover, for both skin and wound samples,
community analysis and viral reads obtained through deep sequencing of clinical swab samples showed significant
improvement with the use of the improved method.
Conclusion: Use of this method may increase the efficiency and data quality of microbiome studies from low-
biomass samples.
Keywords: DNA purification, Bacteriophage, Skin microbiome
Background
The role of the microbiome in human health and disease
has become increasingly recognized over the past decade
[1]. Methodological improvements in sample processing,
sequencing, and bioinformatics are crucial to advance
studies of the phylogenetic and functional diversity of
the microbes colonizing the human body. The bacterial
fraction of the microbiome is often the focus of such
studies, revealing associations between bacterial commu-
nity composition or gene expression and disease states
[2]. However, in recent years, the viral component of the
microbiome has been gaining attention as well. Particu-
larly notable are viruses that infect bacteria (phages),
which may modulate microbial community composition
and physiology within the microbiome [3, 4]. While
most viral studies have focused on the gut microbiome
due to its high microbial load, the skin microbiome is
also of high interest for its contribution to dermato-
logical disease states [5, 6]. In addition, the skin is a
major site of infection (e.g., in diabetic patients) and thus
the microbiome of skin and wounds is relevant to highly
morbid diseases. However, analysis of the skin virome is
methodologically challenging, due at least in part to the
low biomass obtained from typical noninvasive sampling
procedures, such as swabbing. Indeed, [7] recently
highlighted the need for attention to methodological
issues in skin microbiome studies.
Several studies have made progress in optimizing the
methodology of skin microbiome studies with a focus on
the bacterial composition. Sampling methods of varying
invasiveness have been compared (e.g., swab vs. biopsy)
[8, 9] and DNA extraction methods and kits have been
studied, in particular to improve the representation of
Gram-positive organisms through increased physical and
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: chen@chem.ucsb.edu
1Department of Chemistry and Biochemistry, University of California, Santa
Barbara, CA, USA
2Program in Biomolecular Sciences and Engineering, University of California,
Santa Barbara, CA, USA
Full list of author information is available at the end of the article
Verbanic et al. BMC Microbiology          (2019) 19:214 
https://doi.org/10.1186/s12866-019-1586-4
chemical lysis [10–12]. Bioinformatic analysis has also
been a target for optimization, such as in comparing
sequencing methods [10] and variable regions of the
16S rRNA gene to best analyze community compos-
ition [13, 14].
Despite this progress, relatively little work has been
done to optimize DNA recovery from the phage fraction
of the skin microbiome, which presents unique chal-
lenges. Sequencing the virome requires shotgun sequen-
cing of genomic DNA preparations due to the lack of
conserved genes. Although phages outnumber bacteria
in terms of particle number, the small size of their
genomes means that typically only a small proportion of
the DNA in a sample represents phage genomes [15].
Thus, viral sequencing depth is often limited in low bio-
mass samples, inhibiting downstream bioinformatic pro-
cessing for contig assembly, community recapitulation,
and functional annotation [16]. In addition, use of whole
metagenome sampling cannot discern between reads
associated with virus-like particles (VLPs) and those as-
sociated with lysogenic phages that are integrated into
their hosts’ genomes as prophages [17]. A common solu-
tion to this problem is to purify the VLPs, i.e., separate
VLPs from other microbiota, ultimately enabling greater
viral sequencing depth and discernment of genomes as-
sociated with VLPs from prophages. Methods have been
developed and characterized for VLP purification from
high-biomass samples like feces [17] or collected from
large volumes of dilute sample, such as seawater [18].
Also, most VLP purification methods require a separate
sample to be used for characterizing the bacterial frac-
tion, thus introducing a source of variation into the
analysis if one wishes to characterize the virome simul-
taneously with the bacterial fraction. Clinical scenarios
may also hamper collection of multiple replicate sam-
ples. Therefore, while these methods can be applied to
skin microbiome samples [6], there is nevertheless a
need to develop and characterize streamlined protocols
maximizing the yield of DNA from VLPs obtained from
typical clinical skin and wound samples.
Here we detail a methodology, modified from previ-
ous work [6, 18], for swabbing and sample processing
that utilizes fractionation and extraction to simultan-
eously produce both viral-enriched (VLP) and whole-
metagenomic samples from a single, low-biomass
human skin or wound swab. Modifications include re-
serving the swab tip and pellet after centrifugation,
utilizing more lysis methods, and adjusting reagent
concentrations and volumes. We quantify viral DNA
enrichment and total viral and bacterial DNA yields in
model samples using this method. We also use this
procedure to process clinical samples, demonstrating
improved recovery of phage DNA for downstream se-
quencing and characterization.
Results
Recovery of phage and bacterial DNA released from
swabs
In this procedure, material from a single swab is sepa-
rated into a VLP fraction and ‘remainder’ fraction by
centrifugation (Additional file 1: Figure S1). In brief, the
VLP fraction is treated with DNase I to digest free DNA,
VLPs are precipitated, and capsids disrupted by sodium
dodecyl sulfate (SDS) and proteinase K. VLP nucleic
acids are purified by exposure to cetyltrimethylammo-
nium bromide (CTAB), phenol-chloroform extraction,
and ethanol precipitation. For the remainder fraction
and for unfractionated samples, cells are disrupted by
chemical and physical lysis and DNA recovered using a
commercial kit.
To better understand the recovery of phage and
bacterial DNA from a skin or wound swab, we use mock
samples of known concentration, composed of M13
phage and an F- strain of E. coli (i.e, non-host strain).
Phage and cells were mixed together in a 19:1 ratio and
diluted to approximate typical phage:cell ratios and con-
centrations from human and environmental samples
[19]. In addition to DNA extraction itself, there are two
major possible points of loss of material: (1) incomplete
release of material from the swab, and (2) low removal
of material from skin by swabbing. To first address point
(1), we applied the mock sample directly to the swab,
obtained the VLP and remainder fractions, and
measured the yield of DNA recovered. Unfractionated
samples were also analyzed as a control.
The amount of M13K07 phage and bacterial DNA
extracted from each fraction (VLP and remainder) and
from the unfractionated sample were determined by
quantitative polymerase chain reaction (qPCR). Recover-
ies (r) are expressed as a fraction of the known total
quantity of phage (rp) and bacteria (rb) in the entire
mock sample (e.g., for an unfractionated sample,
complete recovery of bacterial or phage DNA corre-
sponds to rb = 1 and rp = 1, respectively). To a first
approximation, we expect that, upon fractionation by
non-equilibrium centrifugation, all bacteria are pelleted
in the remainder fraction (expected rb = 1 in the remain-
der and rb = 0 in the VLP fraction), while phages remain
evenly dispersed in solution (i.e., since the VLP and re-
mainder fractions are equal volume, expected rp = 0.5 in
both fractions). We also define yield of bacteria (yb) and
phage (yp) as the ratio of the observed recovery to the
expected recovery, expressed as a percentage.
Without fractionation, the recovery of bacterial DNA
(rb = 0.45 ± 0.04 (yb = 45%)) and phage recovery (rp =
0.27 ± 0.04 (yp = 27%)), across sample loads, indicated
that recovery for phage was somewhat less efficient than
for bacterial DNA (Fig. 1). For fractionated samples, in
the remainder fraction, rb = 0.56 ± 0.08 (yb = 56%) and
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rp = 0.11 ± 0.04 (yp = 22%) across sample loads, similar to
yields from the unfractionated samples. In the VLP frac-
tion, rb = 0.006 ± 0.003 (yb is undefined given an expect-
ation of 0% recovery) while rp = 0.78 ± 0.09 (yp = 160%)
across sample loads (Fig. 1). The apparent phage yield
over 100% in the VLP fraction, corresponding to unex-
pected enrichment in the supernatant, may be due to inac-
curacies in quantitation of the stock phage concentration
(e.g., conversion factors do not account for compositional
or structural irregularities of the phage). Such biases do
not affect comparisons of yields between unfractionated
samples and remainder and VLP fractions. In the VLP
fraction, the ~ 85-fold decrease in cell DNA recovery and
~ 5-fold increase in phage DNA recovery, compared to
unfractionated or the remainder fraction, indicates a sub-
stantial ~ 400-fold enrichment of DNA recovery (in terms
of genome copies) from phages compared to cells. If
sequenced, this enrichment would translate into a similar
enrichment of phage DNA reads. The overall yields also
indicate that DNA from roughly half or more of the
phages and cells loaded onto a swab can be recovered in
this protocol.
Amount of DNA released from swabs
Since this protocol is intended to produce samples for
high-throughput sequencing, total recovered mass is an
important metric. Depending on the manufacturer’s
instructions, shotgun sequencing library preparation
begins with 0.01–10 ng per sample. Total recovered
DNA mass in the VLP fractions (phage + bacterial, as
determined by qPCR) ranged from 0.63 ± 0.04 ng (from
sample originally containing 1.9 × 108 virions) down to
1.2 ± 0.09 pg (from sample originally containing 1.9 × 105
virions) (Fig. 2a). The concentration of VLP fractions is
sufficient for low-input metagenomic library preparation
without amplification, with the exception of the 1.9 x
105 virion sample, which was expected to yield insuffi-
cient DNA. From the remainder fractions, the total gen-
omic DNA (gDNA) mass ranged from 27 ± 3 ng (from
sample originally containing 107 cells and 1.9 × 108 vi-
rions) down to 32 ± 5 pg (from sample originally con-
taining 104 cells and 1.9 × 105 virions), which is adequate
for low-input metagenomic library preparation and 16S
rRNA sequencing (Fig. 2a). Thus, swabs containing sam-
ples in this concentration range yield sufficient DNA for
bacterial analysis, and may yield sufficient DNA for
phage analysis if the swab contains at least ~ 106 virions
(depending on the phage).
The number of phage genome reads obtained from
sequencing a VLP sample depends not only on the rela-
tive enrichment of VLP DNA compared to cell DNA,
but also on the relative genome sizes. Since bacterial
genomes are 10–1000 times larger than phage genomes,
if no enrichment is performed, reads from bacterial ge-
nomes typically vastly outnumber reads from phage ge-
nomes. Indeed, without fractionation, M13K07 DNA
represented 1.1 ± 0.5% of the total DNA by mass across
sample loads (Fig. 2c), consistent with expectation for
the initial sample (1.8%, based on E. coli genome size:
4.56MB [20], M13 ssDNA genome size: 8669 nt, and 19:
1 phage:bacteria ratio) and the somewhat lower recovery
of phage compared to bacterial DNA.
Fig. 1 Recovery of bacterial (a) and phage (b) DNA from mock samples
loaded onto swabs in varying amounts. Shown are recoveries for the
VLP fraction (cyan), remainder fraction (gray), and unfractionated (white)
samples, as determined by qPCR. Negative controls for qPCR containing
no template were not quantifiable after 40 cycles of PCR. Error bars
indicate standard deviation among biological triplicates
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In contrast, in VLP fractions, M13K07 DNA repre-
sented 73 ± 13% of the mass of recovered DNA across
sample loads (Fig. 2c), corresponding to a 67-fold in-
crease, on average, in the proportion of phage DNA out
of total DNA, compared to the unfractionated samples.
In a metagenomic sequencing sample, this would corres-
pond to a similar increase in the fraction of reads from
phage DNA. In terms of the apparent phage:cell ratio
based on recovered DNA, which was approximately 12:1
in the unfractionated samples, fractionation enriched the
VLP fraction to an apparent phage:cell ratio of ~ 2000:1
to ~ 12,000:1 (Fig. 2b).
Limit of detection of phage swabbed from human skin
Having validated the method using phage:cell mixtures
placed directly onto swabs, we moved to determine re-
covery of DNA when including the second potential
source of loss, swabbing from human skin. An M13KO7
phage stock was serially diluted ten-fold and samples
were loaded onto human skin, then swabbed immedi-
ately or allowed to dry prior to swabbing. Swabs were
processed analogously to the above experiments. Near
quantitative yield was obtained, for samples in which ~
105 or more virions were loaded onto the skin (Fig. 3).
Lower sample loads than this could not be distinguished
from qPCR background. Wet samples were observed to
have consistently higher yields than dry samples; this
phenomenon may be due to denaturation of phage upon
drying and was also observed for T4, which showed a
pronounced decrease in recovery for dried samples (see
next section). The limit of detection of ~ 105 virions
corresponds to ~ 400 fg of ssDNA.
Recovery of T4 and bacterial DNA from skin swabs
To test the compatibility of other phage morphologies
with this method, analogous experiments were performed
Fig. 2 Mass of DNA recovered from swabs loaded with different amounts of M13 and cells. Total (phage + bacterial) DNA mass recovered as determined
by Qubit (a), recovered phage:cell ratio (b) and DNA composition by mass (c) in different fractions, as determined by qPCR. Negative controls for qPCR
containing no template were not quantifiable after 40 cycles of PCR. Error bars indicate standard deviation among biological triplicates
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using the canonical Caudovirales phage T4, in place of
M13K07, for a skin swabbing experiment. A ΔompC
ΔompF strain of E. coli was selected for this experiment to
avoid the confounding effect of phage adsorption and in-
fection. T4 and E. coli were titered spectrophotometrically
and mixed in a 10:1 ratio (108 virions: 107 cells), loaded
onto skin, then swabbed immediately while wet. DNA re-
covery values were comparable to the M13 experiment. In
the remainder fraction, phage recovery rp = 0.32 ± 0.03
(yp = 64%) and bacterial recovery rb = 0.26 ± 0.04 (yb =
26%) were similar to unfractionated samples (rp = 0.53 ±
0.12 and rb = 0.34 ± 0.08) (Fig. 4a,b). In the VLP fraction,
phage recovery rp = 0.27 ± 0.03 (yp = 54%) and bacterial
recovery rb = 0.004 ± 0.001 (yb is undefined) indicated en-
richment of phage, as expected. Controls in which phage
and cells were applied directly to the swab showed similar
recoveries, consistent with expectation given near quanti-
tative yield from swabs.
Total phage DNA mass recovered is substantially
higher than for M13KO7, consistent with the larger gen-
ome of T4, with the amount of DNA recovered from the
VLP fraction being 5.1 ± 0.6 ng, and DNA recovery from
the remainder fraction being 18 ± 3 ng on average. These
amounts are more than sufficient for typical next-gener-
ation sequencing (NGS) preparation protocols.
The recovered DNA from the VLP fraction was com-
posed of 96 ± 1% T4 DNA by mass, a substantial in-
crease compared to the unfractionated control (32 ± 2%)
(Fig. 4c). This increase is less dramatic than for
M13K07, due to the larger genome size of T4. Apparent
phage:cell ratios after recovery also indicate significant
viral enrichment, as fractionation resulted in a phage:cell
ratio of ~ 700:1 in the VLP fraction, compared to that of
unfractionated controls (~ 17:1) (Fig. 4d).
Swabbing was also performed from dried T4 samples,
but these were found to produce very low yields in the
VLP fraction compared to the analogous M13K07 ex-
periment. However, the remainder fraction of the dried
samples gave T4 DNA amounts comparable to swab
controls, indicating that dried T4 could be recovered
from the skin but was lost in the VLP purification
process. We hypothesized that this was due to capsid
damage that occurred during desiccation on the skin,
which then exposed phage DNA to DNase digestion and
thus reduced DNA purified in the VLP fraction. A plaque-
forming assay was performed to determine the concentra-
tion of viable phage particles after desiccation; indeed, the
VLP fraction from dried T4 produced ~ 100-fold fewer
plaques than the VLP fraction of a wet T4 sample.
Recovery of bacterial and phage DNA from clinical wound
and skin swabs
To test whether this processing method improved recov-
ery of phage DNA from clinical swab samples, swabs
were obtained from normal skin and wounds collected
from patients at a wound clinic and processed in prepar-
ation for high throughput sequencing. We compared the
novel sample preparation method (pilot study 2, or PS2)
to a standard kit-based extraction method (pilot study 1,
or PS1) by measuring dsDNA yields fluorometrically.
Using PS1, only 10% of skin VLP fractions and 25% of
wound VLP fractions yielded detectable DNA. However,
PS2 gave significant improvement, producing detectable
Fig. 3 Quantitative recovery of M13 loaded onto skin and then swabbed immediately (blue) or after drying (orange), as determined by qPCR.
Expected or observed DNA copies per swab is indicated. Complete recovery is indicated by the dotted green line. A negative control (red)
indicates experimental background determined by loading of 1X TE onto skin followed by swabbing and qPCR, and therefore reflects the
combined background from skin, swabbing and extraction, and qPCR reagents. Error bars indicate standard deviation among biological triplicates
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DNA in 30% of skin VLP samples and 100% of wound
VLP samples (Fig. 5). Of VLP samples containing a de-
tectable amount of DNA, PS2 yielded 6.7- and 4.4-fold
greater average DNA concentration for skin and wound
swabs, respectively, compared to PS1. Remainder frac-
tions, which include substantial bacteria, are expected to
contain more DNA, and as expected, nearly all skin and
wound samples produced a detectable amount of DNA
in the remainder fraction. In addition, PS2 gave 3.9- and
16.6-fold higher average DNA concentration compared
to PS1, indicating that PS2 would also improve DNA
yield for whole metagenome studies.
To assess the quality of the extracted DNA, samples
from both studies were sequenced by paired-end
Illumina MiSeq. Bacterial composition of the remainder
fractions was determined by 16S rRNA sequencing using
the V1-V3 loops (Fig. 6a). Both skin and wound samples
from PS1 were largely dominated by Burkholderiaceae, a
well known kit contaminant [22, 23]. However, PS1
wound samples also contained low levels of previously
reported skin colonizers such as Corynebacteriaceae,
Staphylococcaceae, and Pseudomonadaceae [24]. In con-
trast, PS2 skin and wound samples did not suffer from
the same apparent kit contamination as PS1, and PS2
samples appear to contain archetypal skin and wound
microbiomes. On average, the most abundant PS2 skin
community members were commensals and opportunists,
including Corynebacteriaceae, Staphylococcaceae, Proprio-
nibacteriaceae, and Micrococcaceae [24, 25]. PS2 wound
samples had high levels of Staphylococcaceae and
Enterobacteriaceae, as well as lower levels of other previ-
ously reported wound colonizers like Bacteroidaceae,
Campylobacteriaceae, Clostridiales, Porphyrmonadaceae,
Pseudomonadaceae, and Streptococcaceae [26–28]. These
findings confirm that the novel fractionation and extrac-
tion protocol produces high quality DNA sufficient for
Fig. 4 Recovery and mass yield from mock skin and swab samples with phage T4. Bacterial (a) and phage T4 (b) DNA recoveries were
determined by qPCR for a single sample load (1.0 × 108 virions and 1.0 × 107 cells). Negative controls for qPCR containing no template were not
quantifiable after 40 cycles of PCR. DNA composition (c) and phage:cell ratios (d) as determined by qPCR characterize T4 enrichment in the VLP
fraction. Error bars indicate standard deviation among biological triplicates
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sequencing, resulting in improved community recapitula-
tion compared to the kit-based extraction used here.
VLP-enriched samples were shotgun sequenced, and
the quantity of recovered viral DNA was estimated by
mapping quality-controlled reads to the Joint Genome
Institute’s integrated microbial genomes viral analysis
(IMG/VR) metagenomic database (Fig. 6b). On average,
only 1.1 ± 1.2% of PS1 skin reads and 2.2 ± 4.3% of PS1
wound reads mapped to the database. PS2 samples had
significantly higher viral mapping rates, with averages of
15.2 ± 8.9% for skin samples and 7.5 ± 13.2% for wound
samples, which corresponded to higher absolute number
of known viral reads (Additional file 1: Figure S2A).
However, PS2 samples also had higher levels of human
DNA contamination (Additional file 1: Figure S2B).
Although the IMG/VR database is likely largely incom-
plete, these results show that the novel method produces
more known viral reads on average.
Discussion
As microbiome studies advance, there is increasing
interest in the relatively understudied virome. However,
experimental methodology for virome sampling has not
been characterized and optimized as extensively as
methods for bacterial sample processing. A central issue
is the low biomass of phages in samples obtained from
skin and wounds, which leads to insufficient material for
sequencing or inadequate sequencing depth. Previously
reported methods tend to be lengthy, not optimized for
small volume, low-biomass samples, and/or do not re-
tain the non-VLP fraction of the microbiome, requiring
acquisition of a second sample for virome and whole
microbiome analysis. These factors limit practical usage
in a clinical setting.
Here, we describe a streamlined method for preparing
both viral-enriched and whole microbiome samples from
a single, low-biomass skin or wound swab. Using this
method, we produce VLP-enriched samples with several
hundred-fold enrichment of viral DNA and also retain a
whole microbiome fraction. Both fractions typically yield
sufficient quantity of DNA for sequencing library prep-
aration. This method may provide the following practical
benefit in a clinical setting. In addition to only requiring
one swab, in comparison to traditional methods (PS1),
in which the majority of skin and wound VLP samples
did not yield sufficient DNA for further analysis, the
technical improvements presented here (PS2) produce
sufficient VLP DNA from 100% of wound swabs and
30% of skin swabs. The increased yield from this
protocol is likely due to the accumulation of small im-
provements. For example, buffer concentrations were
chosen to facilitate replicable pipetting and reduce total
sample volume, allowing precipitation and extraction steps
to be performed in microcentrifuge tubes and a single
phase-lock gel tube, thus minimizing loss from transfers.
Additionally, we find that the use of ethanol precipitation
for VLP DNA purifiaction is more efficient than column-
based purification. Most of the buffers are not available
off-the-shelf in the concentrations used here, but are easily
prepared and stored as such. The PS2 workup requires
more time at the bench, but is less costly in terms of re-
agents in addition to consistently producing higher DNA
yields than PS1, in turn producing higher quality 16S
rRNA and metagenomic sequencing data.
Fig. 5 Comparison of DNA yields from clinical skin and wound swabs using kit-based extraction (PS1) and the method described here (PS2). DNA
was quantified fluorometrically by Qubit assay. Limit of detection is indicated by the dashed line (LOD for the Qubit dsDNA HS assay = 10 pg/μL
according to supplier documentation [21]). The fraction of samples above the LOD (n) is listed. All negative controls, which were exposed to air
in the collection room or blank extractions, were below the LOD
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This protocol was developed with the goal of capturing
free ssDNA and dsDNA phages, so mock specimens
were chosen accordingly to characterize the protocol
(M13 and T4, respectively). These phages also represent
a number of clinically important phages. As a member
of Inoviridae, M13 is a relative of the clinically
implicated Pseudomonas aeruginosa phage Pf [29]. T4 is
a member of the canonical dsDNA Caudovirales family,
which have previously been shown to be prominent
members of the healthy skin virome [6]. We noted that
T4 survived poorly on the dessicated environment of the
skin compared to M13; this may or may not be relevant
Fig. 6 Comparisons of DNA composition from clinical skin and wound swabs using kit-based extractions (PS1) and the method described here
(PS2). For the remainder fraction, bacterial community composition was deteremined by 16S rRNA sequencing (a). Composition was summarized
by averaging the relative abundance of taxa at the Family level across sample type (skin or wound). Families with > 2% average relative
abundance are shown. Recovery of viral DNA in the VLP-enriched fraction was estimated by shotgun sequencing and read mapping to the IMG/
VR viral metagenome database (b). Percentage of reads mapped per sample are plotted here, and mean percentages are compared by t-tests
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depending on whether a study is intended to survey the
viable phages. However, an important caveat of the
present work is that the procedure is not optimized for
lipid-encapsulated or RNA viruses. Additionally, in mock
samples, phage:cell stock solutions were only prepared
in an approximately 10:1 ratio, and variations of this ra-
tio were not tested. Nevertheless, the clinical samples
presumably varied in phage:cell ratio and other factors.
Although only a small proportion (typically < 1%) of
the total bacterial DNA was found in the VLP fraction,
the large molecular weight of bacterial DNA translates
into a large mass fraction relative to phage DNA. This
effect is pronounced in the case of M13, a very small
phage (~ 8 kb ssDNA), for which ~ 70% of the VLP frac-
tion consisted of phage DNA. We anticipate that ~ 70%
thus represents a lower bound on the mass fraction of
phage DNA in realistic settings where multiple viral spe-
cies are recovered. As expected, the effect is less notice-
able in the case of T4 (~ 123 kb dsDNA). Thus, despite
the lack of lengthy purification steps (e.g., CsCl gradient
centrifugation), most reads from a sequencing run using
the VLP DNA would be expected to derive from phages.
We applied this method in the clinic and found that it
dramatically reduced the amount of reagent and consum-
able contaminants detected in 16S rRNA sequencing data.
Additionally, the method produced VLP-enriched samples
with higher viral read mapping rates than the kit-based
extractions. However, the viral read mapping rates were still
relatively low, which is likely due to high human DNA
contamination and an incomplete viral reference database.
We hypothesize that the high level of human DNA con-
tamination was due to increased DNA yields and insuffi-
cient DNase I digestion, which can be remedied with
higher nuclease concentrations and increased incubation
times. While IMG/VR is the most comprehensive viral
metagenome database available [30], database matching is
insensitive to novel viruses, which could account for a large
proportion of the DNA; it is estimated that only 10–60% of
viral metagenomes align to reference databases [31, 32].
Use of this protocol could have several benefits for virome
and microbiome studies, including increased patient re-
cruitment due to minimal swabbing, improved experimen-
tal design using paired VLP and remainder fractions,
reduced failure rate of DNA extraction from individual
swabs, and improved detection of low abundance phages.
Conclusions
With rapid advancements in microbiome studies, the
frequently overlooked virome is gaining interest. How-
ever, investigation of healthy and diseased human vir-
omes from whole metagenome samples can be hindered
by low-biomass samples. To overcome these challenges,
VLP purification methods have been developed. How-
ever, previously reported methods are not compatible
with small volume, low-biomass samples and do not re-
tain the non-VLP fraction of the microbiome, requiring
separate samples for virome and whole microbiome ana-
lysis. Here, we describe a method for preparing both
viral-enriched and whole microbiome samples from a
single, low-biomass skin swab to facilitate the study of
viromes and microbiomes in dermatological diseases.
Using this method, we produce VLP-enriched samples
composed of > 70% viral gDNA with up to 80% yield of
viral gDNA and less than 1% yield of bacterial gDNA.
The remaining whole microbiome fraction is retained in
this process, allowing paired VLP and whole metagen-
ome sequencing. In a clinical setting, this method im-
proves both microbial community analysis as well as the
number of viral reads, demonstrating that technical
improvements can significantly impact the quality of se-
quencing data from low-biomass samples.
Methods
Phage and bacterial sample preparation
Mock samples were composed of M13KO7 phage and
BL21(DE3) E. coli (NEB C2527), or T4 phage and KJ740
E. coli (CGSC 12151). The virion density of phage stocks
was determined spectrophotometrically as follows.
Absorbance was measured at 269 nm and 320 nm and
converted to virions/mL by the following equation: vi-
rions/mL = [(A269 nm - A320 nm) x (6 × 10
16)]/genome
length (8669 bp for M13KO7, 168.903 kb for T4) [33]. 5
mL cultures of E. coli were inoculated by a single colony
and grown in Luria broth (LB) overnight in the presence
of 100 μg/mL ampicillin for strain BL21(DE3) or 10 μg/
mL tetracycline for strain KJ740. Cell density of E. coli
overnight cultures was measured by optical density at
600 nm (OD600) with 4- and 10-fold dilutions, and con-
verted to cells/mL using a conversion factor of 3.2 × 108
cells/mL per OD600 unit. This conversion factor was
experimentally determined by comparing OD600 mea-
surements and colony-forming unit (CFU) counts of
overnight cultures. Known concentrations were used to
create a mixed phage and cell stock solution in a 19:1
ratio, for final concentrations of 9.5 × 106 virions/μL and
5.0 × 105 cells/μL, in 0.5X TE, 0.5X LB (phage stock was
diluted in 1x TE and cells were diluted in LB). For
M13KO7 viral enrichment experiments, the mixed stock
was 10-fold serially diluted 3 times in LB to create a
sample range of 9.5 × 105–9.5 × 103 virions/μL (5.0 ×
104–1.0 × 102 CFU/μL), and 20 μL of each dilution was
loaded directly onto a sterile swab. In the T4 viral en-
richment experiment, one mixed stock was created at
5.0 × 106 virions/μL (5.0 × 105 CFU/μL).
Swabbing from human skin
All swab experiments were performed with sterile Copan
FLOQSwabs 520C. Three healthy volunteers were enrolled
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after obtaining informed consent according to procedures
approved by the UCSB Human Subjects Committee and
Institutional Review Board (Protocol 4-18-0190 and 2-18-
0059). M13KO7 phage alone was diluted serially in 1X ster-
ile TE, for a concentration range from 1.9 × 108 to 1.9 × 102
virions/μL. For skin sampling experiments, skin on the left
forearm of the volunteer was wiped with 70% ethanol.
Then, sample was applied to the skin (20 μL for T4 experi-
ments or 10 μL for M13K07 experiments), covering an area
of approximately 0.25 cm2, and either swabbed immediately
or allowed to dry for 30min. The swab was pre-wetted with
sterile 1X TE and then rotated 10 times over a ~ 1 cm2 area
(length of the swab tip = 1 cm) with gentle pressure
(Levine’s technique). The yield of phages and bacteria re-
covered from such a swab reflects two steps: gathering of
material from the skin, and release of material from the
swab. To separately quantify the yield of phage and cells re-
leased from the swab, the same volume of the stock dilution
series was applied directly to a different swab. Swabs
containing sample were processed further within 30min.
Negative controls were performed by pipetting an equal
volume of 1X TE onto the skin and following the procedure
outlined above.
Fractionation of virus-like particles (VLPs)
After swabbing, the swab tip was inserted into a 1.5 mL
microcentrifuge tube and snapped at the 30mm break-
point. 500 μL of sterile 1X TE was added to the tube,
and the tube was vortexed for 2 min at maximum speed
on a multitube vortex adapter to resuspend the sample.
Samples were then centrifuged at 16,000 x g for 2 min to
pellet cells. 250 μL of supernatant was transferred to a 2
mL microcentrifuge tube for immediate VLP precipita-
tion (the VLP fraction). The remaining 250 μL of super-
natant, pelleted cells, and swab tip (the ‘remainder’
fraction) were kept in the original tube and stored at −
20 °C before proceeding to DNA extraction.
Isolation of DNA from virus-like particles
To digest free DNA in the VLP fraction, 2 μL of 126x
DNase I reaction buffer (441 mM MgCl2, 63 mM CaCl2)
and 2.5 μl DNase I (5 units, NEB) were added to the VLP
fraction, mixed by inversion, and incubated at 37 °C for
30 min. DNase I was inactivated by incubation at 75 °C
for 10 min. VLPs were precipitated by adding 25 μL ster-
ile 1X TE (pH 8.0), 2.5 μL 0.5M EDTA (pH 8.0), 250 μL
formamide, 7 μL glycoblue (15 mg/mL), and 1.1 mL
100% ethanol, followed by incubation at − 20 °C for 1 h
and centrifugation for 1 h at > 10,000 x g at 4 °C. Pellets
were washed with 500 μL of ice cold 70% ethanol and
re-pelleted by centrifugation for 30 min at > 10,000 x g
at 4 °C. Pellets were dried for 1 h at room temperature in
a vacufuge before being resuspended in 152 μL sterile
1X TE (pH 8.0).
Viral capsids were disrupted and digested by adding
19.6 μL of 10% SDS and 21.4 μL proteinase K (20 mg/
mL) to the resuspended VLPs, followed by incubation at
55 °C for 1 h. Then, 32 μL of 5M NaCl and 25 μL
CTAB-NaCl were added followed by incubation at 65 °C
for 10 min. The 250 μL sample was then transferred to a
phase lock gel tube (5PRIME PLG Light) and mixed with
250 μL of 25:24:1 phenol:chloroform:isoamyl alcohol by
inversion. Phases were separated by centrifugation at
1500 x g for 5 min. In the same tube, 24:1 chloroform:
isoamyl alcohol extraction was performed twice and cen-
trifuged as described above, and the 250 μL aqueous
phase was transferred to a 2 mL microfuge tube. DNA
was precipitated by adding 27.5 μL of 3M sodium acet-
ate (pH 5.2), 1 μL Glycoblue (15 mg/mL), and 1.5 mL
100% ethanol followed by incubation at − 80 °C for 1 h
and centrifugation at > 13,000 x g at 4 °C. Pellets con-
taining DNA were washed with 500 μL ice cold 70%
ethanol, centrifuged at > 13,000 x g at 4 °C for 30 min,
dried for 1 h at room temperature in a vacufuge, and
resuspended in 20 μL 1X TE (pH 8.0).
Extraction of genomic DNA from the remainder fraction
and unfractionated samples
Samples were thawed on ice, then vortexed for 2 min at
maximum speed using a multitube vortex adapter to re-
suspend the cells. Keeping the swab in the tube, lysis
was performed by adding 5 μL of 5M NaCl and 45 μL of
Ready-Lyse lysozyme (250 U/μL) (Epicentre), followed
by incubation at room temperature for 30 min. Lysis
continued with addition of 33 μL of proteinase K (20
mg/mL) and 333 μL of PureLink Genomic Lysis/Binding
buffer (Thermo), followed by incubation at 55 °C for 1 h.
Physical lysis was conducted with bead beating by add-
ing 2 g of 0.5 mm glass beads to the sample and vortex-
ing at maximum speed for 10 min using a multitube
vortex adapter. 333 μL of 100% ethanol was added to the
sample and mixed by inversion, and the entire sample
was loaded onto a PureLink Genomic DNA Mini Kit
column (Thermo). DNA cleanup and elution was per-
formed using the kit’s guidelines, with an elution volume
of 25 μL EB.
Collection, processing, and quantification of clinical
samples
Clinical sample collection was performed at Ridley-Tree
Center for Wound Management at Goleta Valley
Cottage Hospital in accordance with protocols approved
by the Cottage Health Institutional Review Board (Study
Protocol 16-52u and 17-48u). We recruited a cohort of
40 wound care patients and collected samples after
obtaining informed consent from the patient. Exclusion
criteria were: patients under the age of 18, in the inten-
sive care unit, or presenting with an unrelated non-
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wound infection. Four clinically classified chronic wound
types were sampled (diabetic, venous, arterial, and pres-
sure ulcers), with ten patients per wound type. Wound
swabs were collected pre- and post-debridement, and a
healthy skin swab was collected from the contralateral
limb. Negative control samples were collected by expos-
ing swabs to air in the collection room for the same dur-
ation as wound and skin swab collection. All swabs were
collected using Levine’s technique as described above for
the mock samples. Swabs were placed back into the dry,
sterile collection tube and stored at 4 °C for no more
than four hours before being processed.
To determine whether the fractionation and purifica-
tion procedures described above affected DNA yield
from swabs obtained in a clinical setting, samples from
20 patients (five patients per wound type; designated as
PS1 samples) were processed using a standard process-
ing protocol, while samples from the other 20 patients
(five patients per wound type; designated as PS2
samples) were processed using the fractionation and ex-
traction methods described in detail above. The standard
processing protocol for PS1 is as follows: 500 μL of
sterile 1x TE was added to the collection tube and
vortexed for 2 min at maximum speed to resuspend the
sample, which was then transferred to a microcentrifuge
tube and centrifuged at 16,000 x g to pellet cells, then
250 μL of supernatant was filtered using a 13mm
0.45 μm polyethersulfone syringe filter to produce the
VLP fraction while the remaining 250 μL supernatant
and pellet constituted the remainder fraction. VLP frac-
tions were subjected to DNase I treatment as described
above, then extracted using the PureLink Viral RNA/
DNA Mini Kit following the manufacturer’s instructions
with an elution volume of 25 μL. The remainder fraction
was extracted using the PureLink Genomic DNA Mini
Kit following the manufacturers instructions with an
elution volume of 25 μL. DNA yields were quantified
fluorometrically using the Qubit dsDNA High Sensitivity
kit on the Qubit 3 instrument, with 5 μL of sample used
per assay.
Quantitative PCR
To generate stocks for qPCR standard curves, M13KO7
and T4 virion DNA was extracted using the PureLink
Viral RNA/DNA Mini Kit and E. coli gDNA was purified
using the PureLink Genomic Mini Kit. Stock concentra-
tions were determined by Qubit ssDNA and dsDNA
High Sensitivity reagents. Stocks were then diluted in
sterile 1X TE to create 10-fold dilution series with the
following concentration ranges: 1.8 × 109–18 copies/μL
for M13K07; 1.7 × 107 to 17 copies/μL for T4; 1.1 × 106
to 11 copies/μL for BL21(DE3) E. coli; 1.3 × 107 to 13
copies/μL of KJ740 E. coli. qPCR primers were designed
on Benchling using Primer3 and were purchased from
Integrated DNA Technologies, generating 100 bp ampli-
cons for M13, T4, and E. coli. Primer sequences used:
M13K07 Forward 5′-TCTGTACACCGTTCATCTGTCC-
3′, M13K07 Reverse 5′-ACCTGCTCCATGTTACTT
AGCC-3′; T4 Forward 5′-AGCGACCCGGTTTCTCAT
TT-3′, T4 Reverse 5′-AAATTACGTCCCGCTGGTGT-3′;
16S rDNA V1 Forward 5′-ATTGAACGCTGGCG
GCAGG-3′, 16S rDNA V1 Reverse 5′-CCCAGACATT
ACTCACCCGTCCG-3′. qPCR experiments were per-
formed using Bio-Rad SsoAdvanced Universal SYBR Green
Supermix and Bio-Rad CFX96 thermal cycler with CFX96
Real-Time PCR Detection System. Final volume of the re-
action was 20 μL, containing 10 μL of SYBR Green Super-
mix, 1 μL of each primer at 10 μΜ, 1 μL template, and 7 μL
of PCR-grade water. 40 cycles of PCR were performed,
followed by melting curve analysis. Concentration data
were converted to mass using genomic molecular weights
determined using the following approximations: molecular
weight (MW) of ssDNA genome = genome length (bases)
× 303.7 g/mol + 79 g/mol; MW of dsDNA genome =
genome length (base pairs) × 607.4 g/mol + 157.9 g/mol.
16S rRNA library preparation, sequencing, and
bioinformatics
16S sequencing libraries were generated by two-step
PCR for each sample. In the first step, V1-V3 loops were
amplified using custom adapter primers composed of
universal 16S primers ‘27F’ and ‘534R’ and Illumina
Nextera indexing adapter sequences. Adapter PCR was
done in 25 μL reactions containing 11.5 μL of template,
0.5 μL of each primer at 10 μΜ, and 12.5 μL of KAPA
HiFi HotStart ReadyMix. 25 cycles of PCR were per-
formed under the following conditions: denaturation at
95 °C for 30 s, annealing at 55 °C for 30 s, and extension
at 72 °C for 30 s. PCR products were purified with 20 μL
AMPureXP beads and eluted into 50 μL of 10 mM Tris
pH 8.5. In the second step, Illumina Nextera XT indices
were added by PCR in 50 μL reactions containing 5 μL
of product from adapter PCR, 5 μL of Index 1, 5 μL of
Index 2, 25 μL of KAPA HiFi HotStart ReadyMix, and
10 μL of water. 8 cycles of PCR were conducted under
the same conditions as step 1. Indexed samples were
purified with 56 μL of AMPureXP beads, eluted into
25 μL of 10 mM Tris pH 8.5, quantified with a Qubit
dsDNA HS kit, normalized and pooled for multiplexing.
Final library QC was done using an Agilent TapeStation
dsDNA 1000 bp kit. The final libraries were sequenced
on an Illumina MiSeq with PE300 V3 chemistry at
UCSB’s Biological Nanostructures Laboratory (BNL)
sequencing core.
Paired-end reads were uploaded to the Quantitative
Insights Into Microbial Ecology Amazon Web Services
Amazon Machine Image (QIIME AWS AMI) (AMI ID:
ami-1918ff72, “qiime-191”) [34]. Initial quality analysis
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was performed with FastQC. Reads were quality
controlled by trimming and quality filtering with
trimmomatic using default settings [35]. Read joining
was performed with QIIME’s joining script (join_paired_
ends.py), using the fastq-join algorithm with default
settings. Joined reads were fed into the open operational
taxonomic unit (OTU) picking pipeline (pick_open_refer-
ence_otus.py) using default settings. Taxonomy was
assigned using the SILVA128 16S reference database
clustered at the 97% identity threshold [36]. The final
Biological Observation Matrix (BIOM) table (without
PyNAST alignment failures) and metadata mapping files
were imported into RStudio using the phyloseq package
for downstream analyses [37]. Samples were sorted from
controls, taxonomy was summarized by agglomerating at
the family level, and absolute OTU abundance was con-
verted to relative abundance per sample and averaged
within sample type (skin vs. wound) within each study
(PS1 and PS2). PS1 and PS2 phyloseq objects were
converted to table format and filtered to remove any
taxa with relative abundance less than 2%, and plotted
with ggplot2 [38].
VLP-enriched library preparation, sequencing, and
bioinformatics
DNA from VLP-enriched samples was amplified by ran-
dom hexamer-primed multiple strand displacement
amplification (GenomiPhi V3, GE Healthcare), following
the manufacturer’s protocol. Amplified DNA was
purified with 40 μL of AMPureXP beads and eluted into
15 μL of 10 mM Tris pH 8.5. Amplified samples were
normalized to 0.2 ng/uL and prepared for shotgun se-
quencing with the Nextera XT kit and Nextera XT indi-
ces, as described by the manufacturer. Indexed samples
were quantified with a Qubit dsDNA HS kit, normalized,
and pooled. Final library QC was done using Agilent
TapeStation dsDNA 5000 bp and 1000 bp kits. Final li-
braries were sequenced on an Illumina MiSeq with
PE150 (PS1) or PE300 (PS2) chemistry, at the UC Davis
Genome Center.
Paired-end reads were uploaded to a custom AWS
AMI (AMI ID: ami-19acbf62, “Chen Lab VMM Basic
Image 1.1”) for bioinformatic processing. Initial quality
analysis was performed with FastQC. Reads were quality
controlled by trimming and quality filtering with trim-
momatic using default settings [35]. All read mapping
steps were performed with Bowtie2 using the –sensitive
and –non-deterministic settings, with mapping summar-
ies printed to file [39]. Reads were first mapped to the
human genome (GRCh38.p13, NCBI accession: GCF_
000001405.39). Reads that did not map to the human
genome were collected and known viral lab contami-
nants were removed by mapping to M13 and fd ge-
nomes. Remaining reads were mapped to the Joint
Genome Institute’s IMG/VR database (IMG_VR_2018-
07-01_4) [30], currently the largest public database of
viral metagenomes. Overall alignment rates were
extracted from the mapping summaries, assembled into
tables, imported to RStudio, and plotted with ggplot2
[38]. T-tests were performed with ggpubr.
Additional file
Additional file 1: Figure S1. Graphical schematic of fractionation
method. Figure S2. Additional comparisons of VLP-enriched DNA
composition from clinical skin and wound swabs using kit-based
extraction (PS1) and the method described here (PS2). VLP-enriched DNA
was shotgun sequenced and mapped to the IMG/VR viral metagenome
database (A) or the human genome (B). Means are compared by t-tests.
Although PS2 samples contained more human DNA than PS1, the
greater fraction of viral reads (Fig. 6b) also translated to a greater
absolute number of reads mapping to IMG/VR. (PDF 702 kb)
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